Direct Compression of Starch Hydrolyzed Oligosaccharide Requires Tight Moisture Control

In veterinary tablet manufacture for companion animal oral solids, starch hydrolyzed oligosaccharide is evaluated as a water-soluble filler-binder in direct compression and wet granulation lines. The regulatory designation of the material as an active ingredient or an excipient is determined by the target species and the intended physiological claim in the filing jurisdiction. Granular feed with a median particle size between 80 µm and 120 µm and a Hausner ratio below 1.25 is targeted for rotary tablet presses operating at 30–70 rpm. When the material is incorporated at 5–12% w/w as a binder and 20–35% w/w as a diluent, tablet breaking force measured according to USP <1217> commonly falls between 25 N and 40 N for uncoated chewable matrices. Disintegration time in water at 37 ± 2 °C using Ph. Eur. 2.9.1 basket apparatus remains below 15 minutes when the formulation moisture equilibrium is kept under 6.0%. On production-scale rotary presses with punch diameters from 9 mm to 12 mm, capping and edge chipping have been observed when compaction force exceeds 35 kN and the granule moisture drops below 3.5%, while punch filming occurs above 60% relative humidity in direct compression suites without dehumidification. Tablets intended for canine oral administration are then film-coated or left uncoated as palatable matrices; uniformity of mass is controlled by Ph. Eur. 2.9.5, and disintegration acceptance criteria follow the approved product specification. Because the material has a high water-soluble fraction, the tablet matrix tends to soften above 50% RH during storage, so aluminium-aluminium blister packaging with desiccant is used when the finished product is distributed in tropical veterinary markets.

Lyophilized injectable matrices intended for cattle and swine parenteral nutrition require a low reducing-sugar oligosaccharide fraction with a dextrose equivalent below 20 and reducing sugar content below 0.5% w/w; higher reducing-sugar grades can react with amino groups in peptide-based active ingredients during freeze-drying at pH above 6.0. The substance is dissolved at 5–10% w/v in Water for Injection at 20–25 °C under low-shear mixing until the solution clears; the resulting osmolality contribution is typically 250–320 mOsm/kg at 10% w/v, verified against Ph. Eur. 2.2.35 or USP <785>. The solution is filtered through a 0.22 µm polyethersulfone membrane and filled into Type I glass vials with a fill volume not exceeding 50% of the vial nominal capacity to allow cake expansion. Published data for this specific configuration is limited; thermal parameters should be verified by freeze-dry microscopy for each formulation batch. The following table presents representative ranges for a 10% w/v solution during development-scale lyophilization.

After lyophilization, the cake must meet USP <790> visible particulates and USP <1> Injections requirements for the target species; residual moisture is controlled below 3.0% by Karl Fischer titration according to USP <921> Method I. Vials are sealed under dry nitrogen with residual oxygen below 2%; if the cake is exposed to ambient humidity above 40% RH during unloading, localised collapse at the vial wall may occur. Incompatibility is recorded with primary amine-bearing active substances and with strongly alkaline buffer systems above pH 7.5 because the reducing end concentration increases through hydrolysis. The final injectable formulation is assessed for sub-visible particulates according to USP <788> and for endotoxins according to Ph. Eur. 2.6.14 at limits justified by the route of administration and target species body weight.

What Limits Capsule Fill Performance in High-Humidity Veterinary Formulations?

Capsule fill performance in high-humidity veterinary formulations is limited by the hygroscopic equilibrium of the oligosaccharide fraction and the moisture exchange with hard gelatin or hydroxypropyl methylcellulose capsule shells. In capsule lines for poultry and swine nutritional products, starch hydrolyzed oligosaccharide is used as a low-dust filler at 15–30% w/w and as a hydrophilic diluent that can reduce disintegration lag time. The angle of repose measured according to Ph. Eur. 2.9.36 should remain below 35° for automatic tamping-pin capsule fillers running at 60,000–100,000 capsules/h; if the moisture content rises above 7.0%, the powder becomes cohesive and fill weight RSD can increase to 4–6%, which exceeds the ±5% content uniformity expectation for uncoated capsules under Ph. Eur. 2.9.6. Hard gelatin capsule brittleness is observed below 35% RH in low-humidity zones, while gelatin crosslinking and delayed disintegration occur when the fill moisture pushes the capsule environment above 65% RH. Filling rooms are therefore maintained at 40–50% RH and 20–25 °C, and capsules are packaged in PVC/PVDC-aluminium blisters with desiccant when the product is intended for tropical distribution. Disintegration is tested by Ph. Eur. 2.9.1 with a limit of 15 minutes in water at 37 ± 2 °C. A narrow particle size distribution with D10 above 40 µm and D90 below 200 µm reduces segregation in dosator-type capsule fillers, but the material should not be combined with hygroscopic salts above 10% w/w because moisture uptake can exceed 8.0% within 24 h at 60% RH and compromise shell integrity.

Neonatal piglet oral powders formulated for gut-support protocols require a water-soluble carbohydrate matrix that disperses in water at 20 °C without lumping, foam generation, or settling. Typically the oligosaccharide is incorporated at 20–35% w/w in a dry blend with electrolytes and organic acids; the blend is sieved through a 150 µm screen using ISO 3310-1:2016 test sieves to ensure D90 below 150 µm. Bulk density is controlled between 0.45 g/mL and 0.60 g/mL; powders with bulk density below 0.40 g/mL create dust clouds and inconsistent scoop dosing, while bulk density above 0.70 g/mL is associated with slower wetting in piglet oral dosers. Moisture specification is set below 6.0% by loss on drying at 105 °C for 2 h according to Ph. Eur. 2.2.32, and water activity is maintained between 0.25 and 0.45 to prevent caking in aluminium-foil sachets stored at 30 °C and 65% RH. On farm, the product is reconstituted at 10 g per 100 mL of clean water and administered by oral dosing or trough; solution pH after reconstitution is between 4.5 and 5.5 to reduce pathogenic bacterial growth during the 2 h administration window. The final powder is required to meet the microbiological criteria of the target jurisdiction, including absence of Salmonella in 25 g and Enterobacteriaceae below 10 CFU/g. Incompatibility is recorded with strong oxidizing agents and with very low pH organic acid premixes below 3.0 where acid hydrolysis can reduce the oligosaccharide molecular weight during storage.

Granule Growth Dynamics in High-Shear Mixer Processing for Ruminant Drenches

Wet granulation of starch hydrolyzed oligosaccharide for ruminant oral drench granules is performed in a high-shear granulator with impeller tip speed between 5 m/s and 8 m/s and chopper speed of 1,500 rpm. The liquid binder, often the oligosaccharide dissolved at 15–20% w/w in water, is added at 8–12% of dry mass over 2–4 minutes; end-point is determined by impeller power consumption reaching 110–130% of baseline. Granules are discharged at moisture 10–12% and dried in a fluid-bed dryer with inlet air temperature 55–65 °C until final moisture is 4.0–5.5%. The sieve fraction between 0.8 mm and 1.6 mm is retained for filling into low-density polyethylene bottles; granule hardness measured by a texture analyzer yields a crushing force of 5–12 N per granule, which is associated with low dust generation and rapid disintegration in artificial cow saliva at 39 °C. In field use, the granules are mixed into drinking water or administered by oral syringe after reconstitution; wetting time in water at 20 °C should be below 60 seconds for a 10 g dose. The final product is tested for uniformity of mass according to Ph. Eur. 2.9.5 where single-dose containers are used, and the residual moisture limit is confirmed by Ph. Eur. 2.2.32. Over-granulation above 16% moisture causes large agglomerates that exceed 2.0 mm and block the oral dosing nozzle; under-granulation below 7% moisture generates fines that adhere to the bottle wall due to static charge. The material should not be dried above 70 °C inlet air temperature because the surface of the granule can develop a hard case that delays wetting and creates an undissolved fraction in the dosing liquid.

When a Low-Dust Medicated Premix Carrier Replaces Corn Starch in Feed Additives

Medicated premix lines for swine and poultry use starch hydrolyzed oligosaccharide as a dust-controlled carrier at 30–50% w/w where corn starch produces excessive fines below 75 µm and poor flow in ribbon mixers. The carrier is blended with active pharmaceutical ingredients in ribbon mixers at fill rates of 60–70% of vessel volume; mixing for 10–15 minutes at 25 rpm yields a coefficient of variation below 5% for tracer studies using iron oxide. Particle size between 100 µm and 250 µm reduces segregation potential during transfer; static charge is observed below 30% RH, requiring equipment grounding and controlled humidification at 40–50% RH. The premix must comply with FDA 21 CFR 558.3 definitions for Type A medicated articles where applicable, and with EU Regulation (EU) 2019/4 for medicated feed, including the carryover limits and manufacturing documentation for active substances. Final premix is incorporated into complete feed at 1–5 kg/tonne depending on the drug loading and species-specific withdrawal times. The carrier is not recommended for high-fat feed matrices above 8% crude fat because oil absorption can form lumps that survive the mill and create mixer dead zones. Water activity of the premix is maintained below 0.55 to limit microbial growth and to avoid hydrolytic degradation of moisture-sensitive antibiotics. Sieve analysis by ISO 3310-1:2016 is used to control the carrier fraction between 100 µm and 250 µm; contract mills report that the dust fraction below 75 µm is normally below 10%, which reduces operator exposure to active pharmaceutical ingredients during weighing and transfer.

Water-based oral solutions for poultry flock administration require a low-viscosity carbohydrate source that remains clear at 25 °C and does not generate browning products during heat treatment or long-term storage. Starch hydrolyzed oligosaccharide is dissolved at 10–25% w/v in purified water; solution viscosity at 25 °C measured with a Brookfield rotational viscometer is typically 5–15 mPa·s, which remains compatible with proportioner pumps set at 0.1–1.0% injection ratio. The pH is adjusted to 5.0–6.5 with citric acid or sodium citrate; if the pH is above 7.0, residual reducing ends can initiate Maillard-type reactions with primary amines and cause yellowing during terminal sterilization at 121 °C for 15 minutes. Sterile filtration through 0.22 µm polyethersulfone membranes before filling is used where terminal sterilization is not feasible due to heat-sensitive additives. Final solution is checked for clarity against Ph. Eur. 2.2.2 and for bacterial endotoxins according to Ph. Eur. 2.6.14, with an acceptance limit appropriate for the target species and intended drinking-water use. In hot climates, stabilised solution packaged in high-density polyethylene jerry cans should be protected from direct sunlight because UV exposure accelerates reducing-end oxidation and can lower the solution pH below 4.0 after 30 days at 40 °C. The material should not be blended with quaternary ammonium disinfectants at high concentration because phase separation and precipitation have been observed when the solution ionic strength exceeds 150 mS/m; separate dosing lines or flushing cycles are required when the product is administered through existing drinking-water systems. The final specification includes a total aerobic microbial count below 10² CFU/mL and total yeast and mould count below 10¹ CFU/mL unless the product is terminally sterilised, in which case sterility is demonstrated according to Ph. Eur. 2.6.1.